These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

596 related articles for article (PubMed ID: 34419139)

  • 1. Targeting Akt in cancer for precision therapy.
    Hua H; Zhang H; Chen J; Wang J; Liu J; Jiang Y
    J Hematol Oncol; 2021 Aug; 14(1):128. PubMed ID: 34419139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway.
    Polivka J; Janku F
    Pharmacol Ther; 2014 May; 142(2):164-75. PubMed ID: 24333502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the PI3K/Akt signaling pathway in gastric carcinoma: A reality for personalized medicine?
    Singh SS; Yap WN; Arfuso F; Kar S; Wang C; Cai W; Dharmarajan AM; Sethi G; Kumar AP
    World J Gastroenterol; 2015 Nov; 21(43):12261-73. PubMed ID: 26604635
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Akt in cancer: Mediator and more.
    Revathidevi S; Munirajan AK
    Semin Cancer Biol; 2019 Dec; 59():80-91. PubMed ID: 31173856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the Akt kinase to modulate survival, invasiveness and drug resistance of cancer cells.
    Cassinelli G; Zuco V; Gatti L; Lanzi C; Zaffaroni N; Colombo D; Perego P
    Curr Med Chem; 2013; 20(15):1923-45. PubMed ID: 23410153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting Protein Kinase Inhibitors with Traditional Chinese Medicine.
    Zhang Y; Liu M; Wang J; Huang J; Guo M; Zuo L; Xu B; Cao S; Lin X
    Curr Drug Targets; 2019; 20(15):1505-1516. PubMed ID: 31376819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The PI3K/AKT Pathway as a Target for Cancer Treatment.
    Mayer IA; Arteaga CL
    Annu Rev Med; 2016; 67():11-28. PubMed ID: 26473415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New development of inhibitors targeting the PI3K/AKT/mTOR pathway in personalized treatment of non-small-cell lung cancer.
    Sun Z; Wang Z; Liu X; Wang D
    Anticancer Drugs; 2015 Jan; 26(1):1-14. PubMed ID: 25304988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PI3K/Akt/mTOR inhibitors in cancer: At the bench and bedside.
    Alzahrani AS
    Semin Cancer Biol; 2019 Dec; 59():125-132. PubMed ID: 31323288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Akt-targeted therapy as a promising strategy to overcome drug resistance in breast cancer - A comprehensive review from chemotherapy to immunotherapy.
    Jabbarzadeh Kaboli P; Salimian F; Aghapour S; Xiang S; Zhao Q; Li M; Wu X; Du F; Zhao Y; Shen J; Cho CH; Xiao Z
    Pharmacol Res; 2020 Jun; 156():104806. PubMed ID: 32294525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of PI3K inhibitors: lessons learned from early clinical trials.
    Rodon J; Dienstmann R; Serra V; Tabernero J
    Nat Rev Clin Oncol; 2013 Mar; 10(3):143-53. PubMed ID: 23400000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting AKT/PKB to improve treatment outcomes for solid tumors.
    Iida M; Harari PM; Wheeler DL; Toulany M
    Mutat Res; 2020; 819-820():111690. PubMed ID: 32120136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting mTOR for cancer therapy.
    Hua H; Kong Q; Zhang H; Wang J; Luo T; Jiang Y
    J Hematol Oncol; 2019 Jul; 12(1):71. PubMed ID: 31277692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The phosphoinositide-3-kinase-Akt-mTOR pathway as a therapeutic target in breast cancer.
    Lauring J; Park BH; Wolff AC
    J Natl Compr Canc Netw; 2013 Jun; 11(6):670-8. PubMed ID: 23744866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the PI3-kinase/Akt/mTOR signaling pathway.
    Hassan B; Akcakanat A; Holder AM; Meric-Bernstam F
    Surg Oncol Clin N Am; 2013 Oct; 22(4):641-64. PubMed ID: 24012393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New inhibitors of the mammalian target of rapamycin signaling pathway for cancer.
    Albert S; Serova M; Dreyer C; Sablin MP; Faivre S; Raymond E
    Expert Opin Investig Drugs; 2010 Aug; 19(8):919-30. PubMed ID: 20569080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Current Status and Future Role of the Phosphoinositide 3 Kinase/AKT Signaling Pathway in Urothelial Cancer: An Old Pathway in the New Immunotherapy Era.
    Liu ST; Hui G; Mathis C; Chamie K; Pantuck AJ; Drakaki A
    Clin Genitourin Cancer; 2018 Apr; 16(2):e269-e276. PubMed ID: 29199023
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent development of anticancer therapeutics targeting Akt.
    Morrow JK; Du-Cuny L; Chen L; Meuillet EJ; Mash EA; Powis G; Zhang S
    Recent Pat Anticancer Drug Discov; 2011 Jan; 6(1):146-59. PubMed ID: 21110830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review.
    Costa RLB; Han HS; Gradishar WJ
    Breast Cancer Res Treat; 2018 Jun; 169(3):397-406. PubMed ID: 29417298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PI3K and AKT: Unfaithful Partners in Cancer.
    Faes S; Dormond O
    Int J Mol Sci; 2015 Sep; 16(9):21138-52. PubMed ID: 26404259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.